Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
721-740 of 1,694 trials

Relapsing Multiple Sclerosis: Remibrutinib vs. Ocrelizumab

We are studying whether remibrutinib is as effective and safe as ocrelizumab for people with relapsing multiple sclerosis after switching treatments. This trial will help us understand the best options for managing the disease.

Relapsing Multiple SclerosisConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineNeurology

TAVI Patients: Ticagrelor vs Aspirin Study

We are comparing the safety and effectiveness of Ticagrelor and Aspirin for patients after Transcatheter Aortic Valve Implantation. This study aims to see which treatment may lead to fewer serious health events and complications.

Aortic Stenosis>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Lobular Breast Cancer: Capivasertib and Fulvestrant Study

We are studying a new treatment combination for patients with high-risk lobular breast cancer to see if it improves cancer control and safety compared to standard therapy.

Invasive Lobular Breast Carcinoma≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Pulmonary Arterial Hypertension: Ralinepag Study

We are studying the long-term safety and effects of ralinepag in patients with pulmonary arterial hypertension. This trial aims to see how it impacts walking ability, heart health, and overall quality of life.

Pulmonary HypertensionConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementCardiologyPulmonology

Gastroesophageal Adenocarcinoma: MK-2870 with Pembrolizumab and Chemotherapy

We are studying a new treatment combination for patients with advanced gastroesophageal adenocarcinoma. The goal is to evaluate its safety and how well it may help manage the disease.

Gastroesophageal CancerSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesOncology

Long-Term Safety Study of Dabrafenib and Trametinib

We are evaluating the long-term safety of dabrafenib and trametinib for patients who have benefited from these treatments in previous studies. This study helps ensure continued access to these medications for those who need them.

Non-Small Cell Lung CancerMetastatic Melanoma1-2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Complement 3 Glomerulopathy: Study of Iptacopan

We are evaluating the safety and effectiveness of iptacopan for patients with complement 3 glomerulopathy. The study aims to see if it can reduce protein levels in urine and improve kidney function.

C3 Glomerulopathy1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementNephrology

Lupus Nephritis: LNP023 Treatment Study

We are studying the safety and effectiveness of LNP023 in adults with active lupus nephritis. The goal is to see if it helps improve kidney function compared to standard treatments.

Lupus Nephritis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNephrologyRheumatology

Gastro-Enteropancreatic Neuroendocrine Tumors: RYZ101 Treatment

We are studying a new treatment, RYZ101, for patients with advanced GEP-NETs that have progressed after previous therapy. The trial compares RYZ101 to standard care to see if it improves patient outcomes.

Gastroenteropancreatic Neuroendocrine TumorsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOncology

C3 Glomerulopathy: Iptacopan Study

We are studying the long-term safety and effectiveness of iptacopan for individuals with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis. This research aims to understand how well the treatment works in improving kidney health.

C3 Glomerulopathy>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Relapsing Multiple Sclerosis: Remibrutinib vs. Teriflunomide

We are studying whether remibrutinib is more effective than teriflunomide in reducing relapses for individuals with relapsing multiple sclerosis. The trial also examines the safety and impact of both treatments on daily life.

Relapsing Multiple Sclerosis>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteNeurology

Multiple Myeloma: CC-92480 Combination Study

We are exploring a new treatment combination for people with relapsed or refractory multiple myeloma. The study aims to assess safety and how well it works compared to standard treatments.

Relapsed or Refractory Multiple MyelomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Crohn's Disease: Vedolizumab with Upadacitinib

We are studying whether a combination of vedolizumab and upadacitinib helps improve symptoms in adults with moderately to severely active Crohn's disease compared to vedolizumab alone.

Crohn's Disease>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Cardiovascular Disease: Gene Analysis for Statin Treatment

We are studying whether a gene analysis strategy can help people at risk of cardiovascular disease better tolerate statins and reduce side effects. This trial compares this approach to standard treatment methods.

Patients at Risk of Cardiovascular Disease6-12 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

HIV-1 Treatment: Bictegravir/Lenacapavir for Kids and Teens

We are studying a new combination medication for children and adolescents with HIV-1 to see how well it works and how safe it is. The trial will also check if young patients find the medication easy to take.

HIV-1 Infection6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Dilated Cardiomyopathy: Risedronate Treatment

We are studying whether Risedronate can improve heart function in patients with dilated cardiomyopathy caused by a Troponin T gene mutation. We also want to assess its safety and impact on physical performance.

Dilated Cardiomyopathy1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Advanced Solid Tumors: Datopotamab Deruxtecan Study

We are studying a new treatment for patients with advanced or metastatic solid tumors to see how well it works and its safety when used alone or with other cancer drugs.

Various Types of CancerEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Type 1 Diabetes: Sotagliflozin for Kidney Health

We are investigating whether sotagliflozin can improve kidney oxygen levels in people with type 1 diabetes and chronic kidney disease. This study aims to understand its effects over three months of treatment.

Type 1 Diabetes with Kidney Complications6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyInternal MedicineNephrology

Preventing Opioid-Induced Constipation in Advanced Cancer Patients

We are comparing two laxatives to see which one better prevents constipation in patients with advanced cancer starting opioid pain treatment. This study will also assess quality of life and side effects.

Advanced Cancer≤3 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOncology

Volrustomig for Advanced Non-Small Cell Lung Cancer

We are studying the safety and effectiveness of volrustomig combined with chemotherapy and other drugs for patients with advanced or metastatic non-small cell lung cancer. This research aims to find better treatment options for this condition.

Non-small Cell Lung CancerSolid TumorsSQ, NSQ NSCLCEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology